Clinical Pathways in T2D Care: Overcoming Inertia, Implementing Innovation

Statement of Need

Clinicians treating patients with T2D need to know how to choose and optimally use incretin therapies that have activity against common comorbidities in T2D, including obesity and CVD. Over the past decade there have been several new classes of drugs developed for individuals with T2D and/or obesity. These agents can provide the means for improving a patient’s quality of life (QoL) and clinical outcomes, but it can take years before new treatments are adapted by HCPs in daily clinical practice. All too often, therapeutic inertia significantly delays needed treatment intensification, putting people with T2D at risk for poor outcomes.

This CMEO digital monograph serves to highlight the presentations of a 2-day educational activity, moderated by Timothy Garvey, MD, which focused on co-occurrence of obesity with elevated A1C and other cardiometabolic risk factors, applications of incretin therapy, and intensification strategies and therapies in the management of T2D.

After participating in the activity and earning your credit, please click this link to reflect on the activity to earn extra credit: https://earnc.me/CuuhSl

Learning Objectives

At the conclusion of this activity, learners will be able to better:

Assess the impact and interplay of obesity with elevated A1C and other cardiometabolic risk factors in individuals with T2D
Evaluate GLP-1 RA and GIP/GLP-1 RA incretin therapies for T2D based on MOA, safety, efficacy, and benefits beyond glycemic control
Incorporate appropriate evidence-based intensification strategies and therapies to the care of individuals with T2D

Financial Support

This activity is supported by an educational grant from Lilly.

Target Audience

U.S.-based endocrinologists, physician associates (PAs), nurse practitioners (NPs), and pharmacists involved in the care of patients with T2D

Credit Information

Jointly Accredited Provider

In support of improving patient care, CME Outfitters, LLC, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Interprofessional (IPCE) 1.0

This activity was planned by and for the healthcare team, and learners will receive 1.00 Interprofessional Continuing Education Credit for learning and change.

Physicians (ACCME) 1.0

CME Outfitters, LLC, designates this Enduring Material for a maximum of 1.00 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Nurses (ANCC) 1.0

This activity is designated for 1.00 contact hours.

California Residents: This continuing nursing education activity was approved by the California Board of Registered Nursing. CME Outfitters LLC’s provider number is CEP15510.

Pharmacists (ACPE) 1.0

This application-based activity is approved for 1.00 contact hours ( 0.1 CEUs) of continuing pharmacy credit (JA0007185-0000-24-010-H01-P).

PAs (AAPA) 1.00

CME Outfitters, LLC, has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 1.00 AAPA Category 1 CME credits. Approval is valid until 02/28/25. PAs should only claim credit commensurate with the extent of their participation.

ABIM MOC 1.0

Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 1.00 medical knowledge MOC points in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

MIPS Improvement Activity

Completion of this accredited CME activity meets the expectations of an Accredited Safety or Quality Improvement Program (IA_PSPA_28) for the Merit-based Incentive Payment Program (MIPS). Clinicians should submit their improvement activities by attestation via the CMS Quality Payment Program website.

Disclosure Declaration

Dr. Garvey reports the following financial relationships:

Advisory Boards/Consultant: Allurion; Alnylam Pharmaceuticals, Inc.; Boehringer Ingelheim; Eli Lilly and Company; Fractyl Health, Inc.; Inogen; Merck & Co., Inc.; Novo Nordisk; Pfizer Inc.; and Zealand Pharma U.S., Inc.

Clinical Trials: Site principal investigator for multi-centered clinical trials sponsored by his university and funded by Eli Lilly and Company; Epitomee; Neurovalens; Novo Nordisk; and Pfizer Inc.

Non-Profits: Consultant on advisory board for the Milken Family Foundation

Data Monitoring Committee: Member of Data Monitoring Committee for phase 3 clinical trials conducted by Boehringer-Ingelheim and Eli Lilly and Company

The following individuals have no financial relationships to disclose:

Jeffrey Helfand, DO (Peer Reviewer)
Albert Eubanks, Jr., RN (Peer Reviewer)
Evan Luberger (Planning Committee)
David Modrak, PhD (Planning Committee)
Susan H. Yarbrough, CHCP (Planning Committee)
Sandra Caballero, PharmD (Planning Committee)
Sharon Tordoff (Planning Committee)

Obtaining Credit

Post-tests, credit request forms, and activity evaluations must be completed online (requires free account activation), and participants can print their certificate or statement of credit immediately (70% pass rate required).